This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Charles River (CRL) Advances in Gene Therapy With Vigene Buyout
by Zacks Equity Research
The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Duke Energy (DUK) Brand Starts Building 250MW Solar Project
by Zacks Equity Research
Duke Energy (DUK) announces the 250-MW Pisgah Ridge Solar project will supply power to three corporations, once its construction is completed by 2022-end.
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 15.53% and 3.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ETF Strategies to Hedge Against Inflation
by Neena Mishra
Here are some ways to protect your portfolio from rising inflation.
Teladoc (TDOC) Q4 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings result reflects revenue gains, more than offset by flared-up expenses.
Company News for Feb 18, 2021
by Zacks Equity Research
Companies in the news are: CRL, VIR, LODE, CLPS
Charles River Laboratories (CRL) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 12.74% and 4.63%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?
by Zacks Equity Research
Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).
Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings
by Zacks Equity Research
LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.
Why Charles River (CRL) Could Beat Earnings Estimates Again
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River (CRL) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.
Charles River (CRL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Growth Investors Will Love Charles River (CRL)
by Zacks Equity Research
Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.
Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More
by Zacks Equity Research
Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Charles River (CRL) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River (CRL) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.
Charles River Laboratories (CRL) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 24.41% and 7.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Q2 Earnings Roster for Aug 5: HUM, CRL & More
by Zacks Equity Research
The healthcare sector is expected to have benefited from solid demand for medical products and services in Q2, given the rising incidence of coronavirus cases as well as an ageing U.S. populace.
Should You Buy Charles River Laboratories (CRL) Ahead of Earnings?
by Zacks Equity Research
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Charles River (CRL) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West
by Zacks Equity Research
Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West